Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1985 3
1986 1
1987 2
1995 1
1996 2
1998 6
1999 6
2000 7
2001 9
2002 15
2003 12
2004 26
2005 38
2006 38
2007 27
2008 30
2009 33
2010 57
2011 52
2012 45
2013 53
2014 47
2015 49
2016 57
2017 45
2018 45
2019 31
2020 35
2021 34
2022 39
2023 43
2024 22

Text availability

Article attribute

Article type

Publication date

Search Results

812 results

Results by year

Filters applied: . Clear all
Page 1
Rasagiline.
Siddiqui MA, Plosker GL. Siddiqui MA, et al. Drugs Aging. 2005;22(1):83-91; discussion 93-4. doi: 10.2165/00002512-200522010-00006. Drugs Aging. 2005. PMID: 15663351 Review.
Rasagiline also possesses neuroprotective properties that are independent of its MAO inhibitory activity. ...Rasagiline has shown significant beneficial effects as monotherapy in the treatment of early Parkinson's disease. ...
Rasagiline also possesses neuroprotective properties that are independent of its MAO inhibitory activity. ...Rasagiline has sh
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled trials.
Yan R, Cai H, Cui Y, Su D, Cai G, Lin F, Feng T. Yan R, et al. Eur J Neurol. 2023 Apr;30(4):1118-1134. doi: 10.1111/ene.15651. Epub 2022 Dec 11. Eur J Neurol. 2023. PMID: 36437702 Review.
METHOD: Randomized controlled trials enrolling PD patients treated with selegiline, rasagiline, safinamide or zonisamide as adjuvant therapy to levodopa were identified. ...The surface under the cumulative ranking results showed that safinamide 100 mg and rasagiline
METHOD: Randomized controlled trials enrolling PD patients treated with selegiline, rasagiline, safinamide or zonisamide as adjuvant …
Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis.
Binde CD, Tvete IF, Gåsemyr JI, Natvig B, Klemp M. Binde CD, et al. Eur J Clin Pharmacol. 2020 Dec;76(12):1731-1743. doi: 10.1007/s00228-020-02961-6. Epub 2020 Jul 24. Eur J Clin Pharmacol. 2020. PMID: 32710141 Free PMC article.
METHODS: We performed a systematic literature search identifying randomized controlled trials investigating 4 dopamine agonists (cabergoline, pramipexole, ropinirole, rotigotine) and 3 MAO-B inhibitors (selegiline, rasagiline, safinamide) for Parkinson's disease. We extrac …
METHODS: We performed a systematic literature search identifying randomized controlled trials investigating 4 dopamine agonists (cabergoline …
Rasagiline.
Schapira A, Bate G, Kirkpatrick P. Schapira A, et al. Nat Rev Drug Discov. 2005 Aug;4(8):625-6. doi: 10.1038/nrd1803. Nat Rev Drug Discov. 2005. PMID: 16106586 No abstract available.
Rasagiline in neurodegeneration.
Schapira AH. Schapira AH. Exp Neurol. 2008 Aug;212(2):255-7. doi: 10.1016/j.expneurol.2008.05.002. Epub 2008 May 16. Exp Neurol. 2008. PMID: 18571162 Review. No abstract available.
Rasagiline in Parkinson's disease.
Chahine LM, Stern MB. Chahine LM, et al. Int Rev Neurobiol. 2011;100:151-68. doi: 10.1016/B978-0-12-386467-3.00008-X. Int Rev Neurobiol. 2011. PMID: 21971007 Review.
Rasagiline has been shown to be effective as monotherapy for early PD and as an adjunct to dopaminergic therapy. ...Given the demonstrated benefits of rasagiline, along with its safety and tolerability profile, it has an important role to play in PD therapy....
Rasagiline has been shown to be effective as monotherapy for early PD and as an adjunct to dopaminergic therapy. ...Given the demonst
Rasagiline for the treatment of Parkinson's disease: an update.
Stocchi F, Fossati C, Torti M. Stocchi F, et al. Expert Opin Pharmacother. 2015;16(14):2231-41. doi: 10.1517/14656566.2015.1086748. Expert Opin Pharmacother. 2015. PMID: 26364897 Review.
INTRODUCTION: Rasagiline is a potent, selective, irreversible Monoamine Oxidase-B (MAO-B) inhibitor, developed to prolong the action of dopamine in the brain. ...AREAS COVERED: The objective of this review, performed by a Medline search on the most recent papers investigat …
INTRODUCTION: Rasagiline is a potent, selective, irreversible Monoamine Oxidase-B (MAO-B) inhibitor, developed to prolong the action …
Safety comparisons among monoamine oxidase inhibitors against Parkinson's disease using FDA adverse event reporting system.
Asano H, Tian YS, Hatabu A, Takagi T, Ueda M, Ikeda K. Asano H, et al. Sci Rep. 2023 Nov 6;13(1):19272. doi: 10.1038/s41598-023-44142-2. Sci Rep. 2023. PMID: 37935702 Free PMC article.
Monoamine oxidase B (MAO-B) inhibitors are used to control Parkinson's disease (PD). Selegiline, rasagiline, and safinamide are widely used as MAO-B inhibitors worldwide. ...The tyramine reaction was detected as an AE signal only for rasagiline. Moreover, the REM sl …
Monoamine oxidase B (MAO-B) inhibitors are used to control Parkinson's disease (PD). Selegiline, rasagiline, and safinamide are widel …
Efficacy of rasagiline for the treatment of Parkinson's disease: an updated meta-analysis.
Chang Y, Wang LB, Li D, Lei K, Liu SY. Chang Y, et al. Ann Med. 2017 Aug;49(5):421-434. doi: 10.1080/07853890.2017.1293285. Epub 2017 Mar 15. Ann Med. 2017. PMID: 28293967 Review.
OBJECTIVE: Rasagiline is a second-generation potent selective inhibitor of monoamine oxidase-B. ...CONCLUSIONS: Our results confirm the efficacy of rasagiline in PD. Further studies are required to establish the optimal dose of rasagiline, as well as to deter …
OBJECTIVE: Rasagiline is a second-generation potent selective inhibitor of monoamine oxidase-B. ...CONCLUSIONS: Our results confirm t …
The role of rasagiline in the treatment of Parkinson's disease.
Leegwater-Kim J, Bortan E. Leegwater-Kim J, et al. Clin Interv Aging. 2010 May 25;5:149-56. doi: 10.2147/cia.s4145. Clin Interv Aging. 2010. PMID: 20517484 Free PMC article. Review.
Rasagiline inhibits MAO-B more potently than selegiline and has the advantage of once-daily dosing. ...In addition, rasagiline has been shown to have neuroprotective effects in in vitro and in vivo studies. ...
Rasagiline inhibits MAO-B more potently than selegiline and has the advantage of once-daily dosing. ...In addition, rasagiline
812 results